Shares of Consort Medical plc (LON:CSRT) have received an average recommendation of “Buy” from the six analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is GBX 1,223.25 ($17.17).
Separately, Numis Securities raised Consort Medical to an “add” rating and set a GBX 1,333 ($18.71) price objective on the stock in a report on Thursday, February 8th.
Shares of LON:CSRT opened at GBX 1,164 ($16.34) on Friday. Consort Medical has a 1 year low of GBX 976.09 ($13.70) and a 1 year high of GBX 1,230 ($17.27).
ILLEGAL ACTIVITY WARNING: “Consort Medical plc (CSRT) Given Average Rating of “Buy” by Analysts” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/consort-medical-plc-csrt-given-average-rating-of-buy-by-analysts.html.
Consort Medical Company Profile
Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.
Receive News & Ratings for Consort Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical and related companies with MarketBeat.com's FREE daily email newsletter.